These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 2159843

  • 1. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 2. Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase I inhibitor.
    Ling YH, Tseng MT, Nelson JA.
    Differentiation; 1991 Mar; 46(2):135-41. PubMed ID: 1648523
    [Abstract] [Full Text] [Related]

  • 3. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S, Riou G.
    Biochem Pharmacol; 1994 Aug 30; 48(5):975-84. PubMed ID: 8093110
    [Abstract] [Full Text] [Related]

  • 4. Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
    Bakic M, Chan D, Andersson BS, Beran M, Silberman L, Estey E, Ricketts L, Zwelling LA.
    Biochem Pharmacol; 1987 Dec 01; 36(23):4067-77. PubMed ID: 2825713
    [Abstract] [Full Text] [Related]

  • 5. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL, Nowak B, Plunkett W, Zwelling LA.
    Cancer Chemother Pharmacol; 1994 Dec 01; 34(3):249-56. PubMed ID: 8004759
    [Abstract] [Full Text] [Related]

  • 6. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M, Chan D, Freireich EJ, Marton LJ, Zwelling LA.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [Abstract] [Full Text] [Related]

  • 7. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M.
    J Biol Chem; 1989 Oct 05; 264(28):16411-20. PubMed ID: 2550442
    [Abstract] [Full Text] [Related]

  • 8. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J, Riou G.
    Biochem Pharmacol; 1991 Jun 15; 41(12):1967-79. PubMed ID: 1645555
    [Abstract] [Full Text] [Related]

  • 9. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M.
    Biochemistry; 1991 Apr 23; 30(16):4048-55. PubMed ID: 1850298
    [Abstract] [Full Text] [Related]

  • 10. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Zwelling LA, Chan D, Hinds M, Mayes J, Silberman LE, Blick M.
    Cancer Res; 1988 Dec 01; 48(23):6625-33. PubMed ID: 2846155
    [Abstract] [Full Text] [Related]

  • 11. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC, Ashorn CL, Chan D, Zwelling LA.
    Cancer Res; 1989 Apr 15; 49(8):2052-8. PubMed ID: 2539251
    [Abstract] [Full Text] [Related]

  • 12. Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
    Markovits J, Pommier Y, Kerrigan D, Covey JM, Tilchen EJ, Kohn KW.
    Cancer Res; 1987 Apr 15; 47(8):2050-5. PubMed ID: 3030540
    [Abstract] [Full Text] [Related]

  • 13. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
    Covey JM, Kohn KW, Kerrigan D, Tilchen EJ, Pommier Y.
    Cancer Res; 1988 Feb 15; 48(4):860-5. PubMed ID: 2827887
    [Abstract] [Full Text] [Related]

  • 15. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA, Mitchell MJ, Satitpunwaycha P, Mayes J, Altschuler E, Hinds M, Baguley BC.
    Cancer Res; 1992 Jan 01; 52(1):209-17. PubMed ID: 1309224
    [Abstract] [Full Text] [Related]

  • 16. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs.
    Estey EH, Silberman L, Beran M, Andersson BS, Zwelling LA.
    Biochem Biophys Res Commun; 1987 Apr 29; 144(2):787-93. PubMed ID: 3034264
    [Abstract] [Full Text] [Related]

  • 17. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Kaufmann SH.
    Cancer Res; 1991 Feb 15; 51(4):1129-36. PubMed ID: 1705167
    [Abstract] [Full Text] [Related]

  • 18. Microsomal activation and increased production of 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide (m-AMSA)-dependent, topoisomerase-associated DNA lesions in nuclei from human HL-60 leukemia cells.
    Gorsky LD, Morin MJ.
    Biochem Pharmacol; 1990 May 01; 39(9):1481-4. PubMed ID: 2159306
    [No Abstract] [Full Text] [Related]

  • 19. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH.
    Cancer Res; 1990 Jun 01; 50(11):3311-6. PubMed ID: 2159380
    [Abstract] [Full Text] [Related]

  • 20. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
    Poddevin B, Riou JF, Lavelle F, Pommier Y.
    Mol Pharmacol; 1993 Oct 01; 44(4):767-74. PubMed ID: 8232227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.